HIV Sexual Risk Behavior Over 36 Months of Follow-Up in the World's First HIV Vaccine Efficacy Trial

Abstract

Increased risk behavior among participants in HIV vaccine efficacy trials has been a concern. This study evaluated HIV sexual risk behavior among 5095 HIV-negative men who have sex with men (MSM) and 308 women enrolled in a randomized, double-blind, placebo-controlled efficacy trial of a bivalent rgp120 vaccine at 61 sites, primarily in North America. Sexual risk behavior data were collected at baseline and semiannually for 36 months. Overall, sexual risk behavior did not exceed baseline levels during the trial. Among MSM, younger age (< or =30 years), perceived assignment to vaccine, and nonblack race were associated with an increased probability of unprotected anal sex. Among women, unprotected vaginal sex initially decreased but was statistically equivalent to baseline by 24 months, whereas unprotected vaginal sex with HIV-infected partners decreased from baseline, where it remained throughout the trial. HIV sexual risk behavior did not increase among trial participants; however, it was substantial throughout the trial. Consistently high levels of risk behavior and the association of these behaviors to perceived assignment and demographic variables underscore the need for vigilant HIV risk reduction counseling, informed consent, and educational processes in the context of HIV vaccine efficacy trials.

Pilot Study Assessing HIV Vaccine Trial Readiness Among Female Sex Workers, Injection and Non-injection Drug Users, and Men Who Have Sex with Men in Spain

“…First, we were unable to accurately distinguish whether missing risk behavior data was due to the refusal to answer questions on the part of some participants or to their unawareness of the HIV serostatus or drug using behaviors of their regular or casual partners. Future data collection instruments should account for partners of unknown serostatus, as unprotected anal and vaginal sex in these partnerships has predicted (Bartholow et al 2005;Buchbinder et al 2005). Second, we may have underestimated the prevalence of these behaviors in some groups using interviewer-administered questionnaires due to socially desirable reporting.…”

Issues in Women's Participation in a Phase III Community HIV Vaccine Trial in Thailand

“…Similar results were obtained in other studies using the same product (AIDSVAX) alone, one of the two vaccines in the RV 144 prime-boost protocol. 22,23 Vaccine completion in men and women were about 85%, and both groups were in compliance with the protocol immunization schedule for about 75% of the time. More women (88%) were retained compared with men (85%).…”

The HPV Vaccine and Behavioral Disinhibition

“…Vaccines against sexually transmitted infections (STIs) may indeed raise concerns about behavioral disinhibition among adolescents and consequent sexual debut [1][2][3][4]. Nevertheless, the level of acceptance of the human papillomavirus (HPV) vaccine among parents and adolescents in Western communities remain high [4].…”